VIB Bioincubator - IP Conference 2014

Report
IP [email protected] 2014
Best practices: Univ-Ind
collaborations
Jo Bury, managing director VIB
Istanbul, October 30th-31st, 2014
Policy factors impacting
innovation: The case of
Flanders
Jo Bury, managing director VIB
Flanders anno 1994
• well established support for R&D
• good (life) science
• stars of worldclass
Flanders anno 1994
•
•
•
•
well established support for R&D
good (life) science
stars of worldclass
Innogenetics – Plant Genetic Systems
How can we do better?
SWOT analysis Flanders 1994
• S: - strong science base (champions)
• W: - no structural funding
- brain drain
- no tech transfer
• O: - develop an attraction pole of excellence
- build a knowledge economy
• T: - loose leading position
Benchmarks
•
•
•
•
•
•
Max Planck Society
MRC UK
Karolinska Institutet
Cold Spring Harbor Labs
Salk Institute
HHMI
Preliminary conclusions
•
•
•
•
•
•
Focus on excellence
PI vs Dir as DMU
Combine strenghts
Build critical mass
Build a tech transfer pipeline
Develop a biotech cluster
Business plan
• build a new institute from scratch
o attract the champions
↕
• reunite the champions in 1 SRC
o multisite
o stringent selection
Business plan (2)
• thematic focus:
o GE: molecular mechanism of life
• high level of ambition:
o top 10% WW
• continuous improvement:
o selection / continuation based on excellence
• institution:
o not another granting body
Business plan (3)
• long term financial commitment:
o
o
o
o
significant (30-50%)
22 M€/year
5 years
renewable (if excellent)
• stringent selection of university departments:
o 9/100
• independent structure (SRC):
o board of directors
o own facilities (TTO)
Reduction to practice
• Minister-President:
o visionary (long term view)
o right combination of powers
o April 1994
• government of Flanders:
o April 1995
• foundation by notarial deed:
o July 1995
• operations:
o January 1996
Reduction to practice (2)
Partnership with universities
•
•
•
•
•
university campus
empower univ staff with VIB staff
framework agreement VIB-univ
mutual added value
share return on investment
– Publications: 2 affiliations
– IPR: joint IP (VIB in charge)
VIB today
VIB: Mission
To create groundbreaking knowledge on the molecular
mechanisms ruling life
for the benefit of scientific progress
and the benefit of society
Excellence in science
+
Excellence in tech transfer
VIB state of affairs
•
•
•
•
•
multisite institute (JV with univ)
1350 scientists – technicians (50/50)
76 research groups
8 departments
management agreement (2012-2016)
• 43.8 M€/year
• 5 years
• key performance indicators
Basic [email protected]
Molecular mechanisms
• molecular medecine
– normal growth and development
– health vs disease




neurobiology
cancer
inflammation
cardiovascular
• molecular farming
– normal growth and development
– normal vs stress
Basic [email protected]
• centre of excellence
• important biological questions
• stimulating environment
–
–
–
–
–
VIB grant
research infrastructure
disruptive technologies
dialective environment
institutional integration
Science policy
Making the Difference
• frontline (not me too)
• world class (international competition)
• relevance + quality
performance
=
good record of high impact publications
and patent applications
Results 2013
Results 2013
• 620 peer reviewed publications
• 168 breaktrough articles (68 T1%)
• 70 PhD’s
Publications in top journals (T5%)
180
160
140
120
100
80
60
40
20
0
'95
'96
'97
'98
'99
'00
'01
'02
'03
'04
'05
'06
'07
'08
'09
'10
'11
'12
'13
Excellence in tech transfer
Path towards value creation
Agreements
IPR
Start-ups
An integrated and pro-active team
IP Management
License &
BD deals
Start-up
Projects
Business Development
New Ventures
Assessment
TT Projects
Licensing case

Start-up case
A proactive IP strategy
45
40
35
30
25
non-VIB
20
VIB
15
10
5
95
96
97
98
99
2000
'01
'02
'03
'04
'05
'06
'07
'08
'09
10
11
12
13
0
•
VIB patent estate: 218 patent families
116 partnering agreements signed
140
120
100
80
60
40
20
0
95
96
97
98
99
00
'01
'02
'03
'04
'05
'06
'07
'08
'09
10
11
12
VIB 0
8
8
15
15
34
29
47
65
61
69
59
82
80
94
111 124 116
VIB integrated approach towards start-ups
VIB
POC Fund
Conceptualize
and write
Build IPR business plan
platform
Evaluate
technology
& business
opportunity
Perform
FTO
analysis
Search for
management
Road show to
investors
Facilitate
start-up
and early
stage
Seed Capital
Fund
VIB start-ups: from knowledge to products
608
employees
VIB start-ups: equity investment and exit
8 M€
+ 29 M€
5 M€
+ 25 M€
+ 11 M€
=> Tradesale
5 M€
+
25M€
+ 40 M€
=> IPO
14.5 M€
+ 7.9 M€
+ 5.1 M€
20 M€
+ 15.5 M€
+ 10.7M€
2 M€
+ 5.5M€
2 M€
5 M€
=> IPO => Tradesale
VIB start-ups: a magnet for foreign
investments
• Total investment in VIB start-ups (€)
– VC/private
– IPO/PIPE/SPO
:
:
255.200.000
272.500.000
527.700.000
~ 50% international
Products: therapeutic pipeline
•
13 therapeutics under development, including 1
small compound
VIB as facilitator for the biotech sector
Building networks
Infrastructure
Attracting/consolidating
companies to/in Flanders
Bio-incubator Leuven
UGent Technology Park: Large Cluster in Biotech
the largest R&D hub in AgBio in Europe
Bioaccelerator I
Bioaccelerator II
Ablynx
DevGen
arGEN-X
VIB/UGent
Bayer Crop Science
(former PGS)
Innogenetics
IIC Ugent
Oxyrane, Genohm,
Biogazelle, Feops, Com
& Sciense, Quinvita, BioActor
Fytolab
CropDesign
Anabiotec
1900 employees
VIB Bioincubator
Actogenix, ADX Neuroscience,
Biomaric, BIP, Complix,
Pronota, Seps Pharma, Yakult,
Q-Biologicals
34
Ghent Agrobiotech cluster
Ghent Biomed campus
From science to value
Policy factors impacting
innovation: The case of
Flanders
Jo Bury, managing director VIB
Science policy (2)
Making the right Choices
•
•
•
•
•
•
•
•
selecting on excellence
bottom up approach
strategic plan (15.10)
exposure to SABs
monitoring (w y m i w y g)
evaluation
reward excellence (rotation)
VIB grant allocation ~ performance

similar documents